Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Study sponsor: Bio-Path Holdings, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-12Estimated
Enrollment · participants108Estimated
Source updated2025-03-07Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.